Investor Relations
Mar 23, 2018
OPKO Health Enrolls First Patient in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes MORE >>
Mar 16, 2018
OPKO Health Announces Landmark Study Showing 4Kscore® Test is Strong Predictor of Prostate Cancer Mortality Published in European Urology MORE >>
Mar 01, 2018
OPKO Health Reports 2017 Fourth Quarter Business Highlights and Financial Results MORE >>
Feb 26, 2018
OPKO Health to Announce Fourth Quarter and Year End 2017 Financial Results on March 1, 2018 MORE >>
<< Back
Jan 26, 2018

OPKO Health Announces Leadership Changes at BioReference Laboratories

MIAMI, Jan. 26, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc.(NASDAQ:OPK), announces that Gregory Henderson, M.D., Ph.D., has resigned from his position as President of BioReference Laboratories, an OPKO Health company and the third largest commercial laboratory in the United States, effective immediately.  The Company has begun a search for his replacement and, in the interim, a committee of senior management will assume operational responsibilities. 

"We thank Dr. Henderson for his work at BioReference Laboratories and wish him continued success in his endeavors," said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO Health.  "The Company seeks to appoint an executive with the leadership skills and industry expertise consistent with OPKO's vision for expanding BioReference's role in the rapidly evolving diagnostic business."

About OPKO Health, Inc.

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI® for chemotherapy-induced nausea and vomiting (oral formulation and IV forms marketed by partner, TESARO); OPK88003, a once-weekly oxyntomodulin for type 2 diabetes and obesity that is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and OPK88004, a selective androgen receptor modulator being developed for benign prostatic hypertrophy and other urologic and metabolic conditions. Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia in Phase 2a. We also have various production and distribution assets abroad, multiple strategic investments and an active business development strategy. More information is available at www.opko.com.

SAFE HARBOR STATEMENT

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expectations about BioReference and expanding its role in the rapidly evolving diagnostics business,  as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Company
David Malina, 305-575-4100
Investor Relations

Investors
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com

or

Bruce Voss, 310-691-7100
bvoss@lhai.com

Primary Logo

Source: OPKO Health, Inc.

News Provided by Acquire Media